Eculizumab Therapy in Suspected Late-Onset Atypical Hemolytic Uremic Syndrome in an Adult Kidney Transplant Recipient: A Case Report

Background and Clinical Significance: Atypical hemolytic uremic syndrome (aHUS) is a rare, life-threatening, complement-mediated thrombotic microangiopathy (TMA) that may occur de novo after kidney transplantation. Because its manifestations overlap with more common causes of allograft dysfunction, including rejection, calcineurin inhibitor toxicity, and infection, diagnosis can be challenging. The disease may progress rapidly, making early clinical suspicion and timely etiologic evaluation essential. Case Presentation: We report a 52-year-old man who developed abrupt, severe graft dysfunction approximately 10 years after ABO-incompatible living-donor kidney transplantation. His serum creatinine had remained approximately 2.0 mg/dL after treatment for suspected chronic active antibody-mediated rejection but increased to 6.57 mg/dL at outpatient follow-up and to 8.47 mg/dL on admission after a recent norovirus infection. Initial evaluation considered common post-transplant causes of graft dysfunction, including rejection, calcineurin inhibitor toxicity, and infection-related injury. However, as renal dysfunction progressed and concurrent anemia and thrombocytopenia became evident, TMA was suspected, and a targeted workup was undertaken. Elevated lactate dehydrogenase, decreased haptoglobin, fragmented red blood cells, and allograft biopsy findings supported TMA. No HLA class I or II antibodies were detected, C4d staining was negative, ADAMTS13 activity was preserved, and testing for Shiga toxin-producing Escherichia coli was negative. Genetic testing identified a heterozygous CFH variant (c.3329G>C, p.Gly1110Ala), classified as a variant of uncertain significance. Based on the clinical, hematologic, and histopathologic findings, suspected aHUS was considered the most likely diagnosis. However, ABMR-associated TMA could not be completely excluded. Plasma exchange was complicated by anaphylaxis, and eculizumab was initiated. Hematologic abnormalities subsequently resolved, although renal function did not recover and the patient remained dialysis-dependent. Conclusions: This case highlights the importance of considering TMA when graft dysfunction progresses rapidly or remains unexplained, even many years after kidney transplantation. Early recognition of microangiopathic features and prompt evaluation for the underlying etiology are particularly important when complement-mediated aHUS is suspected, because established acute-on-chronic allograft injury may limit renal recovery despite hematologic response to C5 inhibition.

Authors

Institutions

Publication Details

Journal
Diagnostics
Published
2026-11-19
DOI
https://doi.org/10.3390/diagnostics16223879
Primary Topic
Complement system in diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Eculizumab Therapy in Suspected Late-Onset Atypical Hemolytic Uremic Syndrome in an Adult Kidney Transplant Recipient: A Case Report

Hyosang Kim, Young Joo Jang, Ji Yeon Min
Diagnostics
Complement system in diseases
article

Eculizumab Therapy in Suspected Late-Onset Atypical Hemolytic Uremic Syndrome in an Adult Kidney Transplant Recipient: A Case Report

Hyosang Kim, Young Joo Jang, Ji Yeon Min
article en

Abstract

Background and Clinical Significance: Atypical hemolytic uremic syndrome (aHUS) is a rare, life-threatening, complement-mediated thrombotic microangiopathy (TMA) that may occur de novo after kidney transplantation. Because its manifestations overlap with more common causes of allograft dysfunction, including rejection, calcineurin inhibitor toxicity, and infection, diagnosis can be challenging. The disease may progress rapidly, making early clinical suspicion and timely etiologic evaluation essential. Case Presentation: We report a 52-year-old man who developed abrupt, severe graft dysfunction approximately 10 years after ABO-incompatible living-donor kidney transplantation. His serum creatinine had remained approximately 2.0 mg/dL after treatment for suspected chronic active antibody-mediated rejection but increased to 6.57 mg/dL at outpatient follow-up and to 8.47 mg/dL on admission after a recent norovirus infection. Initial evaluation considered common post-transplant causes of graft dysfunction, including rejection, calcineurin inhibitor toxicity, and infection-related injury. However, as renal dysfunction progressed and concurrent anemia and thrombocytopenia became evident, TMA was suspected, and a targeted workup was undertaken. Elevated lactate dehydrogenase, decreased haptoglobin, fragmented red blood cells, and allograft biopsy findings supported TMA. No HLA class I or II antibodies were detected, C4d staining was negative, ADAMTS13 activity was preserved, and testing for Shiga toxin-producing Escherichia coli was negative. Genetic testing identified a heterozygous CFH variant (c.3329G>C, p.Gly1110Ala), classified as a variant of uncertain significance. Based on the clinical, hematologic, and histopathologic findings, suspected aHUS was considered the most likely diagnosis. However, ABMR-associated TMA could not be completely excluded. Plasma exchange was complicated by anaphylaxis, and eculizumab was initiated. Hematologic abnormalities subsequently resolved, although renal function did not recover and the patient remained dialysis-dependent. Conclusions: This case highlights the importance of considering TMA when graft dysfunction progresses rapidly or remains unexplained, even many years after kidney transplantation. Early recognition of microangiopathic features and prompt evaluation for the underlying etiology are particularly important when complement-mediated aHUS is suspected, because established acute-on-chronic allograft injury may limit renal recovery despite hematologic response to C5 inhibition.

DiagnosticsVol. 16(22)
Soonchunhyang University Hospital Seoul (KR), Asan Medical Center (KR), University of Ulsan (KR), Dankook University Hospital (KR)
Complement system in diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon